Business Context and Reporting Period
Company: Delcath Systems, Inc. (DCTH)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2024
Reporting Period: Preliminary results for the quarter ended September 30, 2024.
Key Financial Metrics
- Estimated Revenue (Q3 2024): Approximately $11.2 million.
- HEPZATO KIT Revenue (U.S.): Approximately $10.0 million.
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics as final financial statements for the quarter have not been completed.
Material Changes and Triggers
The recording of $10.0 million in U.S. quarterly revenue from the commercialization of HEPZATO KIT has triggered the exercise of Tranche B warrants issued under the March 29, 2023 Private Investment in Public Equity (PIPE).
- Warrant Exercise Window: 21 days from the date of this report.
- Exercise Price: $6.00 per share.
- Aggregate Exercise Price: Up to approximately $25 million.
Guidance, Outlook, and Risks
Management Commentary: Delcath is currently completing its customary quarter-end close and review procedures for the period ended September 30, 2024.
Risks and Contingencies:
- Final results for the third quarter of 2024 may differ from the preliminary estimates provided in this report.
- The filing explicitly states that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the final audited revenue figures for Q3 2024 once the official financial statements are released.
- Confirm the actual number of Tranche B warrants exercised by PIPE holders within the 21-day window.
- Monitor the impact of the potential $25 million capital raise on the company's cash position and share count.
- Review the upcoming 10-Q filing for detailed profit, cash flow, and debt metrics not included in this 8-K.